18F-FDG-PET/CT代谢活性可预测经治非小细胞肺癌患者纳武利尤单抗早期治疗反应
本研究纳入24例经治非小细胞肺癌患者,在纳武利尤单抗治疗前及治疗后1个月行18F-FDG-PET/CT,计算SUVmax、MTV和TLG。结果显示,18F-FDG-PET/CT对部分缓解和疾病进展的预测概率均显著高于CT,多因素分析证实纳武利尤单抗给药后18F-FDG摄取为独立预后因素。
要点
- 纳武利尤单抗治疗后1个月,18F-FDG-PET/CT预测部分缓解的概率为100% vs CT的29%(p=0.021)。
- 18F-FDG-PET/CT预测疾病进展的概率为100% vs CT的22.2%(p=0.002)。
- 多因素分析证实纳武利尤单抗给药后18F-FDG摄取为独立预后因素。
核心结论
- 18F-FDG代谢反应可有效预测纳武利尤单抗治疗1个月时的疗效和生存。
研究设计与样本
- 初步研究,纳入24例经治非小细胞肺癌患者,在纳武利尤单抗治疗前及治疗后1个月行18F-FDG-PET/CT,计算SUVmax、MTV和TLG,并进行PD-L1表达和肿瘤浸润淋巴细胞的免疫组化分析。
主要发现
- 全部患者中,按SUVmax评估的代谢部分缓解率为29%,按MTV评估为25%,按TLG评估为33%,而按RECIST v1.1评估的部分缓解(PR)率为29%(7例)。
- 纳武利尤单抗开始后1个月,18F-FDG-PET/CT预测PR的概率为100% vs CT的29%(p=0.021),预测疾病进展的概率为100% vs CT的22.2%(p=0.002),18F-FDG均显著高于CT。
- 多因素分析证实纳武利尤单抗给药后18F-FDG摄取为独立预后因素。
- PD-L1表达和纳武利尤单抗血浆浓度不能精确预测纳武利尤单抗的早期疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nivolumab, an anti-programmed death-1 (PD-1) antibody, is administered in patients with previously treated non-small cell lung cancer. However, little is known about the established biomarker predicting the efficacy of nivolumab. Here, we conducted a preliminary study to investigate whether 18F-FDG-PET/CT could predict the therapeutic response of nivolumab at the early phase. METHODS: Twenty-four patients were enrolled in this study. 18F-FDG-PET/CT was carried out before and 1 month after nivolumab therapy. SUVmax, metabolic tumour volume (MTV), and total lesion glycolysis (TLG) were calculated. Immunohistochemical analysis of PD-L1 expression and tumour-infiltrating lymphocytes was conducted. RESULTS: Among all patients, a partial metabolic response to nivolumab was observed in 29% on SUVmax, 25% on MTV, and 33% on TLG, whereas seven (29%) patients achieved a partial response (PR) based on RECIST v1.1. The predictive probability of PR (100% vs. 29%, p = 0.021) and progressive disease (100% vs. 22.2%, p = 0.002) at 1 month after nivolumab initiation was significantly higher in 18F-FDG on PET/CT than in CT scans. Multivariate analysis confirmed that 18F-FDG uptake after administration of nivolumab was an independent prognostic factor. PD-L1 expression and nivolumab plasma concentration could not precisely predict the early therapeutic efficacy of nivolumab. CONCLUSION: Metabolic response by 18F-FDG was effective in predicting efficacy and survival at 1 month after nivolumab treatment.
引用
- Kaira K, Higuchi T, Naruse I, et al. Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC. Eur J Nucl Med Mol Imaging. 2017. PMID: 28828507. doi:10.1007/s00259-017-3806-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。